3.36

0.30% 0.010

Cytomx Therapeutics Inc (CTMX)

Overview News Price History Option Chain Financials Discussions Forecast

Cytomx Therapeutics Inc stock is traded at $3.36, with a volume of 1.43M. It is up +0.30% in the last 24 hours and down -8.20% over the past month. CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.

Previous Close:

$3.35

Open:

$3.34

24h Volume:

1.43M

Relative Volume:

0.37

Market Cap:

$732.14M

Revenue:

$35.54M

Net Income/Loss:

$-59.14M

P/E Ratio:

-9.2384

EPS:

-0.3637

Net Cash Flow:

$-80.19M

1W Performance:

-2.89%

1M Performance:

-8.20%

6M Performance:

-36.84%

1Y Performance:

+90.91%

1-Day Range:

$3.28

$3.385

1-Week Range:

$3.28

$3.535

52-Week Range:

$1.775

$8.21

Cytomx Therapeutics Inc Stock (CTMX) Company Profile

Name

Cytomx Therapeutics Inc

Sector

Healthcare (1080)

Industry

Biotechnology (604)

Phone

650.515.3185

Address

151 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA

Employee

Twitter

@cytomxinc

Next Earnings Date

2026-08-06

Latest SEC Filings

CTMX's Discussions on Twitter

Compare CTMX vs VRTX, REGN, ARGX, RVMD, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CTMX Cytomx Therapeutics Inc	3.36	760.47M	35.54M	-59.14M	-80.19M	-0.3637
VRTX Vertex Pharmaceuticals Inc	505.75	133.25B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	803.48	82.16B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	851.29	54.80B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	203.71	43.99B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	347.48	40.62B	5.76B	514.49M	1.10B	4.4813

Cytomx Therapeutics Inc Stock (CTMX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-16-26	Upgrade	JP Morgan	Neutral → Overweight
Jan-20-26	Initiated	Guggenheim	Buy
Sep-22-25	Initiated	Cantor Fitzgerald	Overweight
Sep-17-25	Resumed	Barclays	Overweight
Jul-31-25	Initiated	Oppenheimer	Outperform
May-15-25	Upgrade	H.C. Wainwright	Neutral → Buy
Apr-14-25	Resumed	Piper Sandler	Overweight
May-28-24	Upgrade	Piper Sandler	Neutral → Overweight
May-09-24	Upgrade	Wedbush	Neutral → Outperform
May-06-24	Upgrade	Jefferies	Hold → Buy
Apr-22-24	Upgrade	JP Morgan	Underweight → Neutral
Nov-14-22	Downgrade	BMO Capital Markets	Outperform → Market Perform
Jul-07-22	Downgrade	Jefferies	Buy → Hold
Jul-07-22	Downgrade	Mizuho	Buy → Neutral
Jul-07-22	Downgrade	Piper Sandler	Overweight → Neutral
Jul-07-22	Downgrade	Wedbush	Outperform → Neutral
Jun-24-22	Initiated	BMO Capital Markets	Outperform
Jan-18-22	Upgrade	Barclays	Underweight → Overweight
Nov-15-21	Initiated	BTIG Research	Buy
May-28-21	Downgrade	Barclays	Equal Weight → Underweight
Mar-29-21	Initiated	JP Morgan	Overweight
Mar-23-21	Upgrade	Jefferies	Hold → Buy
Sep-22-20	Downgrade	Guggenheim	Buy → Neutral
Jun-01-20	Downgrade	Jefferies	Buy → Hold
May-14-20	Reiterated	H.C. Wainwright	Buy
Mar-24-20	Upgrade	Wedbush	Neutral → Outperform
Mar-04-20	Initiated	Barclays	Equal Weight
Nov-20-19	Initiated	Guggenheim	Buy
Nov-11-19	Downgrade	Wedbush	Outperform → Neutral
Jun-13-19	Initiated	Mizuho	Buy
May-14-19	Initiated	Cantor Fitzgerald	Overweight
Mar-11-19	Initiated	Barclays	Overweight
Nov-26-18	Initiated	Piper Jaffray	Overweight
Oct-15-18	Initiated	Goldman	Neutral
Sep-13-18	Initiated	H.C. Wainwright	Buy
Jun-01-18	Initiated	SunTrust	Buy
Jan-05-18	Initiated	Citigroup	Buy
Sep-08-17	Initiated	Wedbush	Outperform
Mar-27-17	Initiated	H.C. Wainwright	Buy
Mar-02-17	Initiated	Instinet	Buy
Jan-03-17	Downgrade	Oppenheimer	Outperform → Perform
Nov-02-15	Initiated	Oppenheimer	Outperform

View All

Cytomx Therapeutics Inc Stock (CTMX) Latest News

01:44 AM

CytomX Therapeutics (NASDAQ:CTMX) Stock Rating Upgraded by Wall Street Zen - MarketBeat

01:44 AM

Aug 14, 2026

Point72’s 3.6% CytomX Therapeutics (CTMX) stake detailed in amended filing - Stock Titan

Aug 14, 2026

Kynam Capital reports 9.96% CytomX Therapeutics (CTMX) ownership in Schedule 13G/A - Stock Titan

Aug 14, 2026

Aug 13, 2026

CTMX Maintained by JP Morgan -- Price Target Lowered to $11.00 - GuruFocus

Aug 13, 2026

CytomX Therapeutics (NASDAQ:CTMX) Given New $11.00 Price Target at JPMorgan Chase & Co. - MarketBeat

Aug 13, 2026

Bank of America Corp DE Has $47.95 Million Position in CytomX Therapeutics, Inc. $CTMX - MarketBeat

Aug 13, 2026

MSN Money - MSN

Aug 13, 2026

Aug 12, 2026

CytomX Therapeutics: Promising Varseta-M With Comfortable Runway (NASDAQ:CTMX) - Seeking Alpha

Aug 12, 2026

Aug 10, 2026

CTMX Maintained by Guggenheim -- Price Target Lowered to $14.00 - GuruFocus

Aug 10, 2026

Guggenheim cuts CytomX stock price target to $14 on model update - Investing.com South Africa

Aug 10, 2026